While hypofractionated radiotherapy (RT) can shorten the duration of a patient’s treatment course through fewer treatments at higher doses, can the procedure result in more side effects? The phase 3 NRG-GU003 randomized clinical trial by Mark K. Buyyounouski, MD, MS, and colleagues examined the outcomes of patients with prostate cancer who underwent hypofractionated postprostatectomy radiotherapy (HYPORT) or conventionally fractionated postprostatectomy radiotherapy (COPORT) to determine if HYPORT is noninferior to COPORT regarding ...